Those of you who use Continuous Airway Pressure (CPAP) machines may want to check what brand you are using.

The Federal Drug Administration (FDA) recently issued a an alert regarding safety issued for Phillips Respironics' DreamStation 2 CPAP machines, which are used for treatment of obstructive sleep apnea.

According to the FDA, the machine is having thermal issues which have been connected to patient injuries.

The agency says they have received reports connecting the device to fire and smoke issues and even burns while the machine is in use.

The agency first became aware of this issue during a routine analysis of the MDRs that were submitted to the FDA. The agency noted a sharp increase, more than 270 reports, in the number of MDRs associated with thermal issues of the machine between Aug. 1, 2023, to Nov. 15, 2023. Before Aug. 1, 2023, the agency had received fewer than 30 MDRs associated with thermal issues with the device since it was cleared for marketing in 2020.

While the FDA continues to analyze and address this issue, the agency is recommending those who use the machine to follow the manufacturer's instructions in the user manual and to inspect and examine the machine for unusual smells or changes in appearances before and after each use.

The agency says it continues to discuss ways to mitigate these issues with the company.

This new safety issue comes as the FDA continues to closely monitor Philips’ handling of the June 2021 recall impacting millions of sleep therapy and respirator machines, including CPAP machines. The polyester-based polyurethane foam used in the recalled machines to reduce sound and vibration can break down and could potentially be breathed in or swallowed, posing possible risks to the person using the device.

The DreamStation 2 were distributed as replacement machines for some users whose machines were affected by the June 2021 recall.